Reports on the choice of hypoglycemic drug in GS patients are scarce, and some case studies suggest that SGLT2 inhibitors might lead to exacerbated hypotension and heightened diabetic ketoacidosis risk in their case (Ahmed et al., 2021; Yang et al., 2023). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.